Covalent drugs could provide pharmacological advantages like prolonged duration of action and enhanced potency over non-covalent drugs. In recent years, their discovery has been boosted by rational design and facilitated by emergence of new technologies in proteomics. This enables drug identification with higher selectivity by identifying their binding site.
With their unique mechanistic properties that differentiate them from non-covalent inhibitors, covalent drugs can be administered at lower doses and frequencies reducing off-target events and increasing patients’ compliance. In addition, they can be an effective strategy for low vulnerability targets where high levels of occupancy are needed to generate the desired physiological outcomes. Covalent therapeutics can also be a strategy to overcome drug-resistance mutations in the gene encoding the target protein like in case of the epidermal growth factor receptor (EGFR).
Join this webinar to learn more about the new emerging technologies to develop covalent therapeutics.
Simon Haydar, SVP & Head, Integrated Drug Discovery Solutions, Aragen Life Sciences
Simon Haydar comes with more than two decades of rich experience in leading integrated drug discovery projects. Over the years, he has spearheaded various discovery projects to develop novel oral therapies for different therapy areas. His functional expertise spans across areas such as discovery R&D leadership, licensing due diligence, biotech alliances & partnerships, external R&D activities and mergers and acquisitions.
Prior to joining Aragen, Simon has held various leadership roles at Syngene International Limited, Assembly Biosciences, Eli Lily, GSK and Pfizer.Message Presenter
Who Should Attend?
- Research Scientist; Senior Scientist; Principal Scientist; Lead Scientist; Associate Director; Director level scientists
- VP, R&D; Chief Scientific Officer, Chief Technology Officer leading discovery research
- Academic and non-profit organization Scientists working on discovery research, integrated discovery
What You Will Learn
Attendees will gain insights into:
- Advantages of covalent drugs
- Advancements in covalent drug discovery
- Covalent vs non-covalent drugs; how covalent drugs can reduce off-target events and increase patient compliance
- Effective strategy for low vulnerability targets, overcoming drug-resistance mutations for gene encoding
Aragen Life Sciences
Aragen Life Sciences is a leading R&D and manufacturing solutions provider for the life sciences industries worldwide. Aragen offers end-to-end integrated or standalone solutions to advance small and large molecule programs from concept to commercialization. Established in 2001, the Company operates through a global network of six sites with a team of 3800+ employees and 450+ PhDs. Its expertise and experience have enabled over 450 customers (including 7 of the top 10 pharma companies globally) in advancing their research programs from early discovery through development and commercialization. Aragen’s innovative mindset, infrastructure, flexible business models, a clear purpose, and proprietary project management platform have enabled it to effectively scale and service large pharma, biotech, agrochemical, and animal health industries globally. Visit www.aragen.com for more details